Cantor Fitzgerald Starts Coverage of Milestone Pharmaceuticals with Overweight Rating and $3 Target
Cantor Fitzgerald initiates Overweight coverage on Milestone, citing Cardamyst’s strong PSVT launch potential and $250-300M peak sales outlook.
/ 3 items
#MIST↓
Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
FDA Approves CARDAMYST: First Self-Administered Nasal Spray for PSVT
Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.